[CAS NO. 26807-65-8] Indapamide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [26807-65-8]

Catalog

HY-B0259

Brand

MCE

CAS

26807-65-8

DESCRIPTION [26807-65-8]

Overview

MDL	-
Molecular Weight	365.83
Molecular Formula	C16H16ClN3O3S
SMILES	O=C(NN1C(C)CC2=C1C=CC=C2)C3=CC=C(Cl)C(S(=O)(N)=O)=C3

For research use only. We do not sell to patients.

Summary

Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy ^[1] ^[4] .

In Vitro

Indapamide (0.1-500 mg/L; 20min) reduces total insulin secretory response to glucose infusions in isolated perfused rat pancreas ^[2] .
Indapamide (1-100 μM) increases osteoblast proliferation and decreased bone resorption ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indapamide (1 mg/kg/d; gastric gavage for 8 weeks) lowers blood pressure in spontaneously hypertensive rats (SHRs) ^[4] .
Indapamide (10 mg/kg/d) decreases pressor response to oxotremorine, noradrenaline, and tyramine in rats ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (11 weeks) ^[4]
Dosage:	1 mg/kg
Administration:	Gastric gavage per day for 8 weeks
Result:	Decreased blood pressure by 16.9 mm Hg. Increased the dp/dt _max , ejection fraction (EF) and fractional shortening (FS).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05294484	Ain Shams University	Pharmacogenomics	March 15, 2022	Phase 4
NCT05013463	University of Calgary	Multiple Sclerosis, Secondary Progressive	October 1, 2021	Phase 2
NCT02710539	University of Roma La Sapienza	Arterial Hypertension	April 2016	Phase 4
NCT05470764	Darnitsa Pharmaceutical Company\|International Pharmaceutical Research Center	Bioequivalence\|Healthy Subjects	May 30, 2021	Phase 1
NCT00980187	LaborMed Pharma S.A.	Hypertension\|Type 2 Diabetes Mellitus	March 2008	Phase 4
NCT03814109	EMS	Arterial Hypertension	April 2022	Phase 3
NCT01172431	West China Hospital	Hypertension\|Renal Insufficiency	September 2010	Phase 4
NCT05103332	Alnylam Pharmaceuticals	Hypertension	November 5, 2021	Phase 2
NCT03722524	Servier Russia	Arterial Hypertension	October 1, 2018
NCT04455178	Shanghai Jiao Tong University School of Medicine	Hypertension	September 23, 2020	Phase 4
NCT00128518	Hospices Civils de Lyon	Hypertension	October 2004	Phase 4
NCT01620788	EMS	Hypertension	November 27, 2019	Phase 3
NCT03626506	Peking University Third Hospital\|University of Michigan\|Peking University	Hypertension	February 13, 2019	Not Applicable
NCT00122811	Imperial College London\|British Heart Foundation\|Institut de Recherches Internationales Servier	Hypertension	November 2000	Phase 4
NCT02699645	The George Institute\|The University of New South Wales	Intracerebral Haemorrhage (ICH)\|Hypertension	September 28, 2017	Phase 3
NCT05110898	Brainfarma Industria Química e Farmacêutica S+A	Hypertension\|Hypertension,Essential	August 1, 2022	Phase 3
NCT03783754	The George Institute\|University of Sydney	Stroke\|Cerebral Small Vessel Diseases\|Intracerebral Hemorrhage\|Vascular Dementia\|Hypertension	August 9, 2018	Not Applicable
NCT01754779	University of Texas Southwestern Medical Center\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Calcium Phosphate Kidney Stones	July 2012	Phase 2
NCT05464745	Darnitsa Pharmaceutical Company\|International Pharmaceutical Research Center	Bioequivalence\|Healthy Subjects	May 19, 2021	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 273.35 mM )

H ₂ O : 0.67 mg/mL ( 1.83 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7335 mL	13.6676 mL	27.3351 mL
5 mM	0.5467 mL	2.7335 mL	5.4670 mL
10 mM	0.2734 mL	1.3668 mL	2.7335 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-

Benzamide, 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoyl-

3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide

Indapamide

SE 1520

S 1520

Lozol

Tertensif

(±)-Indapamide

Racemic indapamide

Fludin

Fludex

Flupamid

Flubest

Indamide

Natrilix

Veroxil

Damide

Ipamix

Tandix

Indaflex

Bajaten

Indamol

Noranat

Arifon

Lorvas

KYD 041

Natrix